No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis
Allen P, Goyal S, Greenwell I, Scribner J, Rangarajan S, Mehta A, O'Leary C, Niyogusaba T, Huen A, Switchenko J, Tarabadkar E, Ayers A, Krishnasamy S, Porcu P, Sethi T, Iyer S, Lechowicz M. No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis. Blood 2021, 138: 2441. DOI: 10.1182/blood-2021-151911.Peer-Reviewed Original ResearchMF/SSWhite blood cell countB patientsNB patientsMedian survivalSézary syndromeInferior survivalSystemic therapyMycosis fungoidesBlack patientsInsurance statusSeattle GeneticsExact testMultivariate Cox proportional hazards modelT-cell receptor clonalityHigh rateCox proportional hazards modelAdvisory CommitteeHigher nodal stageLarge registry studyHigh-risk featuresMulticenter retrospective analysisNumber of comorbiditiesYear of diagnosisKaplan-Meier curvesHow we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome
Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntineoplastic AgentsBexaroteneBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyDelayed DiagnosisDiagnosis, DifferentialElectronsHematopoietic Stem Cell TransplantationHistone Deacetylase InhibitorsHumansInterferon-alphaMaleMycosis FungoidesNeoplasm StagingNeoplastic Stem CellsPhotopheresisPrognosisPUVA TherapyRetinoidsSezary SyndromeSignal TransductionSkin NeoplasmsT-Lymphocyte SubsetsConceptsT-cell lymphomaSézary syndromeMultidisciplinary careCutaneous T-cell lymphoma mycosis fungoidesMycosis fungoides/Sézary syndromeCutaneous T-cell lymphomaLines of therapyAdditional treatment optionsNon-Hodgkin lymphomaDuration of useCumulative drug toxicityEarly referralRecurrent diseaseDiagnostic delayPatients' qualityTreatment optionsCommon subtypeTreatable diseaseRare subsetDrug toxicityLymphomaSyndromeDiseasePresent reviewCare